Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)

NCT00607854 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma
Mantle Cell Lymphoma

Interventions

DRUG: Ibritumomab Tiuxetan (Zevalin)

Sponsor

University Hospital, Bordeaux

Collaborators

[object Object]